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intensive care unit bed). The mean direct medical expenditures
for one patient is 25,858 CZK (€1,034) per year. CONCLU-
SIONS: Based on data from Institute of Health Information and
Statistics of the Czech Republic in 2006 there were 678 760 type
2 diabetic patients in our country. It it roughly 17.5 bilion CZK
(€0.7 bil) per year, counting approximately 20% of total health
care spending in Czech Republic.
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OBJECTIVES: To estimate the annual medical costs attributable
to obesity in diabetic patients. METHODS: This cross-sectional
analysis was based on the 2001–2005 Medical Expenditure Panel
Survey data, a nationally representative sample of the U.S. non-
institutionalized population. A total of 4880 diabetic patients
were identiﬁed based on the ICD-9-CM code:250 after excluding
patients with pregnancy, malignancy, kidney dialysis, immuno-
deﬁciency, or >75years old. Diabetic patients were classiﬁed as
normal (body mass index(BMI):18.5–<25), overweight(BMI:25–
<30), or obese(BMI:30). Medical costs included costs associ-
ated with any treatments except dental problems and injuries.
The parameters for obese patients were estimated using a gener-
alized linear model with a log link function and a gamma distri-
bution after adjusting for the demographic variables. The mean
medical cost was predicted for normal-weight patients using the
parameters estimated from the obese patients. The difference
between the predicted and the observed costs in normal weight
patients was the medical costs attributable to obesity. All costs
were converted to 2005 U.S. dollars using price indices. Data
were analyzed using SAS and SUDAAN. RESULTS: The age-
adjusted prevalence of the study diabetic patients was 2.1% in
normal-weight, 3.9% in overweight, and 9.7% in obese patients
respectively. The average attributable costs to obesity in diabetic
patients were $1,527 (95%CI:$318–$2736). The average attrib-
utable costs to obesity increased as patients became older ($794
for aged 18–50, $1636 for aged 51–64, and $2044 for aged
65–74) and were higher in women ($2679) than men ($139), and
in private insurance ($2185) compared to public insurance
($591). CONCLUSIONS: The prevalence of diabetes in obese
people was approximately ﬁve times higher than in normal-
weight people. The medical costs for obese patients with diabetes
were signiﬁcantly higher than in normal weight patients. The
effective public health intervention aimed at controlling weight in
diabetic patients is recommended to reduce the extra economic
burden of obesity.
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OBJECTIVES: To estimate and compare the economic implica-
tions of insulin glargine (GLAR) and detemir (DET) therapy
initiation in a population with type 2 diabetes mellitus (T2DM)
with a one year time horizon, from major insurers perspectives in
Argentina (union-based and private HMOs). METHODS: Clini-
cal and efﬁcacy parameters and their distributions were based on
Rosenstock’s article (2008), a 52-week randomized treat-to-
target trial which compared clinical outcomes following supple-
mentation of oral glucose-lowering drugs with basal insulin
analogues, DET and GLAR, in T2DM patients. Resource use and
cost values, as well as their distributions, were obtained from
Argentinean published literature, tariffs, databases, experts’
opinion and the international literature. Costs are expressed in
local currency, year 2008 (exchange rate 1€ = 4.79ARG$). Vari-
ability was incorporated in insulin, needles and strips costs,
proportion of DET patients with once daily injection and GLAR
and DET dose per kilogram. Probabilistic sensitivity analysis
(PSA) was carried out based on Monte Carlo simulations with
10,000 iterations. Linear regression analysis was carried out in
order to gauge the relative inﬂuence on the results related to the
uncertainty around each parameter. RESULTS: Annual mean
cost was $2630 for GLAR and $4,092 for DET, implying a 36%
(95%CI 33.2%; 37.9%) total cost saving with GLAR ($1462). A
total of 82.7% of this difference was explained by the lower
average daily dose requirement with GLAR (GLAR 26 UI vs.
DET 42 UI). Savings in test strips, and needles explained 10.2%
and 7.1% of the total difference. In the regression analysis, the
most important parameters explaining variability in total cost
savings were the proportion of DET patients requiring twice
daily injections followed by the insulin dose per patient. CON-
CLUSIONS: In Argentina, Insulin Glargine was associated with
a cost saving of more than one third compared to the use of
Insulin Detemir. Sensitivity analyses conﬁrmed the robustness of
this result.
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OBJECTIVES: To compare the economic impact of the treatment
of acromegaly with two different somatostatin analogues in
Brazil, after the decision of reimbursement of the therapeutic
class by the Brazilian Public Health Care System (SUS) in 2002.
METHODS: Acromegaly treatment cost estimation was based
on secondary data and on a decision analytical model developed
from the Brazilian Public Health Care System Clinical Guideline
for Acromegaly. The strategies of using somatostatin analogues
in depot presentations (octreotide LAR or lanreotide SR) were
compared. The model followed a hypothetical cohort of 276
patients diagnosed with acromegaly for two years. Costing
included direct medical costs, composed by drugs, consultations,
monitoring tests, radiotherapy and hospitalisation, under the
Brazilian Public Health Care System perspective. Data were
extracted from national and international literature, and from
administrative ofﬁcial databases (Ambulatory Information
System, Hospital Information System, Mortality Information
System). Costs are reported in 2005 Reais (R$) and Euros (€).
Ofﬁcial exchange rate was used for currency conversion (2.77
BRL = 1 EUR, Brazilian Central Bank). Sensitivity analysis was
conducted. RESULTS: Octreotide LAR treatment strategy pre-
sented net savings of R$10,448,324 (€3,771,958) to the Brazilian
Public Health Care System when compared to lanreotide SR
treatment strategy in a period of two years. Average annual cost
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per patient was R$27,359 (€9,877) for octreotide LAR and
R$46,287 (€$16,710) for lanreotide SR. Net savings per
patient per year with octreotide LAR were R$18,928 (€6,833).
Sensitivity analysis did not revert results of net savings.
CONCLUSIONS: Monitoring of acromegaly treatment costs
after reimbursement for somatostatin analogues showed that
octreotide LAR is cost-saving compared to lanreotide SR in
Brazil under the Public Health Care System perspective.
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OBJECTIVES: The objective of this study was to estimate cost-
utility of biphasic insulin aspart (BIAsp) versus biphasic human
insulin (BHI) in type 2 diabetes patient’s diagnosed and treated in
tier III urban hospitals in China. METHODS: A published, vali-
dated, peer-reviewed computer simulation model of diabetes (the
CORE Diabetes Model) was used to project short-term results
obtained from a large, 26-week, observational study conducted
across China. 474 Chinese patients were switched from BHI to
BIAsp and results were entered into the model. Complication
cost data and a survey of treatment management practices were
collected from secondary care centres independent of the obser-
vational study, to avoid protocol costs. Market prices of drugs
and glucose monitoring tests were used. Patient baseline charac-
teristics included the mean age (57.9 years), duration of diabetes
(7.98 years) and baseline HbA1c (8.55%). Life expectancy,
quality adjusted life expectancy and total direct medical costs
(complications + treatment costs) were projected over patient
lifetimes (30 years), and were discounted at 3% per annum in
line with local pharmacoeconomic guidelines. RESULTS:
Improved glycemic control and lower hypoglycemic event rates
associated with BIAsp therapy led to an increase in life expect-
ancy (mean  sd) of 0.261 years (10.72  0.174 versus
10.46  0.163) compared to BHI. Quality-adjusted life expect-
ancy increased by 0.53 years (6.94  0.115 versus 6.39  0.10).
BIAsp was associated with increased total lifetime costs per
patient of CNY 2,386 (247,325  5,897 versus 244,939 
6,922). Thus, BIAsp is associated with an incremental cost-
effectiveness ratio (ICER) of CNY 4315 per quality-adjusted life
year (QALYs) gained. Probabilistic sensitivity analysis shows that
the result is robust. CONCLUSIONS: Long term (life time) pro-
jections of the short-term clinical improvements from the
Chinese IMPROVE study suggest that BIAsp is a cost-effective
treatment compared to BHI, with an ICER below what would be
considered cost-effective in China, using cost-effectiveness
thresholds of 2–3 times GDP per capita, suggested by the WHO.
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OBJECTIVES: Type 2 Diabetes mellitus (T2DM) is a frequent
comorbid condition with obesity. The increasing prevalence of
obesity in the USA, coupled with the rising prevalence of T2DM
and the high up-front cost of bariatric surgery, has necessitated
payers to question the cost-effectiveness of bariatric surgery as a
treatment for T2DM. Our analyses compared cost-effectiveness
of the Roux-En-Y gastric bypass surgery with medical manage-
ment for T2DM patients using clinical outcomes data from a
bariatric surgery practice at the University of Minnesota and
modeling these 2-year observational follow-up data to a lifetime
horizon. METHODS: The CORE Diabetes Model was used to
project lifetime clinical and economic outcomes for T2DM
patients undergoing bariatric surgery. The baseline mean HbA1c
(7.7%), age (50.7), body mass index (48.8 kg/m2), gender (22%
male), race/ethnicity, and risk factors were taken the University
of Minnesota cohort (n = 169). Remaining cohort characteris-
tics, transition probabilities, utilities, direct treatment, and com-
plication costs were obtained from published sources. All costs
and clinical outcomes were discounted at 3% per annum.
RESULTS: Average lifetime total direct costs per patient were
$96,696 (3,349) for Roux-En-Y gastric bypass and $77,169
(2,674) for medical management. Discounted life expectancy
and quality-adjusted life years (QALYs) increased by 0.578
(0.470) years and 0.827 (0.501) QALYs, respectively, for
Roux-En-Y gastric bypass compared with medical management.
The resulting incremental cost-effectiveness ratios (ICERs) for
Roux-En-Y gastric bypass compared with medical management
were $33,795/life-year gained and $23,618/QALY gained.
Probabilistic sensitivity analysis demonstrated a 79.3% likeli-
hood of the cost/QALY being $50,000/QALY for Roux-En-Y
gastric bypass compared with medical management. CONCLU-
SIONS: Cost-effectiveness was driven primarily by superior
HbA1c, lipid reductions, and weight loss. The ICERs obtained in
our analyses provide evidence for the long-term cost-effectiveness
of Roux-En-Y gastric bypass as a treatment for T2DM and is
consistent with current threshold values in the USA for health
technology assessment.
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OBJECTIVES: The aim of the study was to evaluate the cost-
utility of insulin glargine versus NPH and premix in patients with
DM2 with baseline HbA1c above 8% and age below 65 years in
Poland. METHODS: The method adapted was a cost utility
analysis with a 40 year time horizon and public payer perspec-
tive. The model used is a DES model based on the UKPDS 68
equations which has the ability to assess the economic impact
and health consequences outlined as the development of
co-morbidities of a reduction in hypoglycemia, an improvement
in glycaemia or both of these at the same time. A cohort of 1000
patients was generated in the model. Glycaemic control has been
incorporated into the model using results from The Health
Improvement Network (THIN) database. Polish costs were
applied in the model and only direct medical costs were consid-
ered in the analysis. Sensitivity analysis was performed. The
study was conducted according to the Polish HTA guidelines. In
the analysis patients were divided into three groups by age and
baseline HbA1c level. RESULTS: When comparing glargine to
NPH the analyses showed that for patients with age <= 65 and
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